Skip to content
Search
Home
About Us
About APLAR
APLAR Milestones
President Message
Committees
APLAR Directors
Executive Committee
Other Committees
Membership
Member National Organizations
Constitution & Terms of Reference
Membership Application
Membership Update
Academy
APLAR Academy
Governance
Membership
Short Course
Upcoming Course
Past Course
Academy Webinar
Upcoming Webinar
Past Webinar
Grand Round
Upcoming Grand Round
Past Grand Round
Discussion Forum
Grand Round Blackboard
ASPIRE Grant
About APLAR ASPIRE
ASPIRE Core Training Modules
ASPIRE Implementation Toolkit
About SIG
AYR
ABOUT AYR
AYR Board
Committee
AYR Membership
AYR Webinar
Upcoming Webinar
Past Webinar
AYR Blackboard
Discussion Forum
Collaboration
APLAR ESOR
ESOR Application
Post Event Submission
Online Submission
EULAR School of Rheumatology
Exchange Programme
Exchange Programe Application
Online Submission
EULAR Exchange Program
APLAR MNO Patronage
Patronage Application
Online Submission
EULAR Collaborations
Center Of Excellence
APLAR CoEs
New Application
Renew CoE Application
Online Submission
Grants and Awards
Grant
COPCORD Grant
Congress Travel Grant
Research Grant
Fellowship Grant
Award
Master Award
Events
Congress
Upcoming Congress
Past Congress
Events
Upcoming Events
Past Events
Gallery
Publications
Published Journal
SIG Publication
COVID – 19 Publication
IJRD
Voice Of APLAR
Patient Education
APLAR Grand Round Blackboard 2024
Step
1
of
2
50%
Question 1
By inhibiting the binding of IL-4 and IL-13 to their respective receptors, which of the following asthma types can be controlled?
Question 1
*
A. Eosinophilic asthma
B. Allergic asthma
C. Neutrophilic asthma
D. Paucigranulocytic asthma
E. Eosinophilic asthma and allergic asthma
Answer with a detailed explanation
E. Eosinophilic asthma and allergic asthma
The pathophysiological mechanisms that underlie allergic and eosinophilic inflammation in asthma are interconnected. There is increasing recognition of the complex relationship in asthma between adaptive immunity, including Th2 cells, and innate immunity, including type 2 innate lymphoid cells. Type 2 inflammation, mediated by cytokines such as IL-4, IL-5, and IL-13, occurs in approximately 50% of patients with asthma. Type 2-high asthma includes overlapping phenotypes, allergic asthma (characterized by increased expression of specific IgE to aeroallergens), and eosinophilic asthma (characterized by blood and/or airway/tissue eosinophilia).
Reference
1. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nature medicine. 2012 May;18(5):716-25
2.Corren J, Ambrose CS, Sałapa K, Roseti SL, Griffiths JM, Parnes JR, Colice G. Efficacy of tezepelumab in patients with severe, uncontrolled asthma and perennial allergy. The Journal of Allergy and Clinical Immunology: In Practice. 2021 Dec 1;9(12):4334-42.
Your Answer is Incorrect
Your Answer is Incorrect
Your Answer is Incorrect
Your Answer is Incorrect
Question 2
Which cytokine is critical for the differentiation of naive helper T cells (Th0 cells) to type 2 helper T cells (Th2 cells)?.
Question 2
*
A. IL-4
B. IL-5
C. IL-6
D. IL-31
E. IL-33
Answer with a detailed explanation
A. The antigen-presenting dendritic cells release IL-4 that induces the resident Th0 cells in lymph nodes to differentiate into Th2 cells.
Reference
1. Noda S, Suárez-Fariñas M, Ungar B, Kim SJ, de Guzman Strong C, Xu H, Peng X, Estrada YD, Nakajima S, Honda T, Shin JU. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased Th17 polarization. Journal of Allergy and Clinical Immunology. 2015 Nov 1;136(5):1254-64.
2. Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nature reviews Drug discovery. 2016 Jan;15(1):35-50.
3.Gieseck III RL, Wilson MS, Wynn TA. Type 2 immunity in tissue repair and fibrosis. Nature Reviews Immunology. 2018 Jan;18(1):62-76.
Your Answer is Incorrect
Your Answer is Incorrect
Your Answer is Incorrect
Your Answer is Incorrect
Your Answer is Incorrect
If you can’t view the question please click
here
.